kr241.60
0.04%
Copenhagen, Oct 24, 04:59 pm CET
ISIN
DK0015998017
Symbol
BAVA

Bavarian Nordic Stock price

kr241.60
+11.00 4.77% 1M
+89.05 58.37% 6M
+52.25 27.59% YTD
+16.60 7.38% 1Y
+17.20 7.66% 3Y
+66.30 37.82% 5Y
-36.90 13.25% 10Y
-161.40 40.05% 20Y
Copenhagen, Closing price Fri, Oct 24 2025
-0.10 0.04%
ISIN
DK0015998017
Symbol
BAVA
Industry

Key metrics

Basic
Market capitalization
kr19.1b
Enterprise Value
kr17.6b
Net debt
positive
Cash
kr1.7b
Shares outstanding
77.9m
Valuation (TTM | estimate)
P/E
13.7 | 20.6
P/S
3.0 | 3.0
EV/Sales
2.7 | 2.8
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
79.2%
Return on Equity
8.7%
ROCE
11.7%
ROIC
12.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr6.5b | kr6.3b
EBITDA
kr2.1b | kr1.9b
EBIT
kr1.4b | kr1.2b
Net Income
kr1.4b | kr913.3m
Free Cash Flow
kr-433.7m
Growth (TTM | estimate)
Revenue
6.1% | 10.9%
EBITDA
12.5% | 84.5%
EBIT
98.0% | 31.8%
Net Income
101.1% | -7.6%
Free Cash Flow
-149.2%
Margin (TTM | estimate)
Gross
53.1%
EBITDA
32.9% | 29.7%
EBIT
22.2%
Net
22.0% | 14.4%
Free Cash Flow
-6.7%
More
EPS
kr17.7
FCF per Share
kr-5.6
Short interest
-
Employees
2k
Rev per Employee
kr3.6m
Show more

Is Bavarian Nordic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Bavarian Nordic Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Bavarian Nordic forecast:

3x Hold
33%
6x Sell
67%

Analyst Opinions

9 Analysts have issued a Bavarian Nordic forecast:

Hold
33%
Sell
67%

Financial data from Bavarian Nordic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6,455 6,455
6% 6%
100%
- Direct Costs 3,027 3,027
16% 16%
47%
3,428 3,428
1% 1%
53%
- Selling and Administrative Expenses 1,062 1,062
14% 14%
16%
- Research and Development Expense 933 933
26% 26%
14%
2,123 2,123
12% 12%
33%
- Depreciation and Amortization 690 690
41% 41%
11%
EBIT (Operating Income) EBIT 1,433 1,433
98% 98%
22%
Net Profit 1,423 1,423
101% 101%
22%

In millions DKK.

Don't miss a Thing! We will send you all news about Bavarian Nordic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Head office Denmark
CEO Paul Chaplin
Employees 1,605
Founded 1992
Website www.bavarian-nordic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today